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BACKGROUND AND PURPOSE
Diltiazem inhibits CaV1.2 channels and is widely used in clinical practice to treat cardiovascular diseases. Binding determinants
for diltiazem are located on segments IIIS6, IVS6 and the selectivity ﬁlter of the pore forming a1 subunit of CaV1.2. The aim of
the present study was to clarify the location of the diltiazem binding site making use of its membrane-impermeable
quaternary derivative d-cis-diltiazem (qDil) and mutant a1 subunits.
EXPERIMENTAL APPROACH
CaV1.2 composed of a1, a2-d and b2a subunits were expressed in tsA-201 cells and barium currents through CaV1.2 channels
were recorded using the patch clamp method in the whole cell conﬁguration. qDil was synthesized and applied to the
intracellular side (via the patch pipette) or to the extracellular side of the membrane (by bath perfusion).
KEY RESULTS
Quaternary derivative d-cis-diltiazem inhibited CaV1.2 when applied to the intracellular side of the membrane in a
use-dependent manner (59  4% at 300 mM) and induced only a low level of tonic (non-use-dependent) block (16  2%
at 300 mM) when applied to the extracellular side of the membrane. Mutations in IIIS6 and IVS6 that have previously been
shown to reduce the sensitivity of CaV1.2 to tertiary diltiazem also had reduced sensitivity to intracellularly applied qDil.
CONCLUSION AND IMPLICATIONS
The data show that use-dependent block of in CaV1.2 by diltiazem occurs by interaction with a binding site accessible via a
hydrophilic route from the intracellular side of the membrane.
Abbreviations
Dil, d-cis-diltiazem; qDil, quaternary derivative of d-cis-diltiazem; SQ32, 428, quaternary benzothiazepine [(cis)-1,3,4,5-
tetrahydro-4-(4-methoxyphenyl)-3-methyl-6- (triﬂuoromethyl)-1-[2-trimethylammonio)ethyl]-2H-1-benzazepin-2-o ne]
Introduction
L-type calcium channels belong to the high-voltage-activated
channel family (isoforms CaV1.1, CaV1.2, CaV1.3 and CaV1.4)
and display a high sensitivity to calcium channel blockers (or
Ca
2+ antagonists) (Catterall et al., 2005). CaV1.2 participates
in excitation–contraction coupling in cardiac and smooth
muscle, action potential propagation in sinoatrial and
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tion and other processes (Striessnig, 1999; Catterall, 2000;
Schulla et al., 2003; Sinnegger-Brauns et al., 2004). Calcium
antagonists are widely used to treat cardiovascular diseases
such as hypertension, angina pectoris and arrhythmias
(Striessnig, 1999; Triggle, 2007). They are a chemically het-
erogeneous group of drugs that exert their therapeutic effects
by inhibiting voltage-gated L-type Ca
2+ channels. The proto-
typical agents of this group are diltiazem (Dil; a benzothiaz-
epinone, BTZ), nifedipine (a 1,4-dihydropyridine, DHP) and
verapamil (a phenylalkylamine, PAA). Single amino acids
determining the sensitivity of L-type channels for calcium
antagonists have been identiﬁed by mutational analysis and
functional studies (Hering et al., 1996; Kraus et al., 1998;
Striessnig et al., 1998, Berjukow et al., 1999 Hockerman et al.,
2000; Dilmac et al., 2003).
The binding sites for PAA and diltiazem share common
amino acid residues but it is assumed that the two classes of
drug access their binding pockets from different sides of
the membrane. There is clear evidence from studies with
quaternary PAA analogues applied via the patch pipette
that this class of CaV1.2 inhibitors interacts with an intrac-
ellular located binding site (Hescheler et al., 1982; Berjukov
et al., 1996). Thus it is widely believed that tertiary PAAs
penetrate the membrane and block CaV1.2 from the cyto-
solic side of the membrane in their protonated form in a
use-dependent manner. CaV1.2 inhibition by diltiazem is
also use-dependent (Lee and Tsien, 1983; Uehara and
Hume, 1985; Smirnov and Aaronson, 1998). Variation of
external and internal pH revealed that diltiazem inhibits
L-type channels in its charged and neutral forms
(Smirnov and Aaronson, 1998). Studies with a structurally
related benzothiazepine [quaternary benzothiazepine
[(cis)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-6-
(triﬂuoromethyl)-1-[2-trimethylammonio) ethyl] - 2H - 1-
benzazepin-2-o ne] (SQ32,428)] suggested, however, an
extracellular location of the diltiazem binding site (Hering
et al., 1993). The latter ﬁnding is in apparent contradiction
with mutational studies indicating that crucial diltiazem
binding determinants overlap with determinants of PAA
sensitivity located deeply in the channel pore (Hering et al.,
1996; Kraus et al., 1998; Berjukow et al., 1999; Hockerman
et al., 2000; Dilmac et al., 2003). Tikhonov and Zhorov
(2008) pointed out that the potential BTZ binding determi-
nants are located in the inner pore of Cav1.2 while some
quaternary BTZ block the channel when applied externally
rather than internally. The authors proposed a molecular
model explaining the interaction with key amino acids of
the putative binding pocket that were identiﬁed in func-
tional studies. Tikhonov and Zhorov (2008) suggest that
drug access occurs via the III/IV domain interface from the
outside of the membrane.
However, to date no study has systematically examined
the extracellular and intracellular action of the therapeuti-
cally used diltiazem on CaV1.2. Therefore we synthesized the
quaternary derivative of d-cis-diltiazem, qDil, and explored
its effects when applied from outside or inside (via the patch
pipette) of the cell membrane. Our data on wild-type and
mutant CaV1.2 clearly demonstrate ‘use-dependent’ intracel-
lular access of qDil to the diltiazem binding pocket in
CaV1.2.
Methods
All chemicals obtained from commercial suppliers were used
as received and were of analytical grade. Melting points were
determined on a Koﬂer hot stage apparatus and are uncor-
rected. The
1H- and
13C-NMR spectra were recorded on a
Bruker Avance DPx200 (200 and 50 MHz).
Synthesis of quaternary diltiazem
Iodomethane, 0.568 g (4 mmol), was added to a solution of
the free base of 0.829 g (2 mmol) diltiazem in 2 mL dichlo-
romethane at room temperature. After 48 h the reaction
mixture was concentrated to dryness. The crude product of
qDil was obtained and recrystallized from isopropanol to
yield 0.807 g (97%) of qDil.
The analysis of this material gave the following results: Mp
178–181°C;
1H-NMR (D2O): d 7.68-7.64 (m, 3H), d 7.38–7.26
(m, 3H), d 6.89 (JA,B = 8.58 Hz, 2H), d 5.04 (q, 2H), d 4.13–4.08
(m, 1H), d 3.96–3.83 (m, 2H), d 3.72 (s, 4H), d 3.42–3.38 (m,
1H), d 3.09 (s, 9H), d 1.80 (s, 3H);
13C-NMR (D2O): d 170.29, d
169.10, d 160.28, d 144.35, d 136.24, d 132.83, d 131.02, d
128.92, d 127.65, d 126.32, d 125.63, d 114.36, d 71.85, d 63.47,
d 55.74, d 54.61, d 50.10, d 44.54, d 20,89.
The purity of qDil was conﬁrmed by high-performance
liquid chromatography and was 98%. The analysis was per-
formed using a Jasco UV-1575 Chromatograph. The station-
ary phase was a 5 mm RP-18e Lichrospher Merck column
(250 mm ¥ 4 mm). As a mobile phase, ammonium acetate pH
6.0 + 0.5% DEA/CAN (50/50) was used.
Cell culture and transient transfection
Human embryonic kidney tsA-201 cells were grown at 5%
CO2 and 37°C to 80% conﬂuence in Dulbecco’s modiﬁed
Eagle’s medium/F-12 supplemented with 10% (v·v
-1) fetal calf
serum and 100 units·mL
-1 of penicillin and streptomycin.
Cells were split using trypsin/EDTA and plated on 35 mm
Petri dishes (Falcon, Franklin Lakes, NJ, USA) at 30–50% con-
ﬂuence 16 h before transfection. Subsequently, tsA-201 cells
were co-transfected with cDNAs encoding wild-type (Gen-
BankTM accession number X15539) or mutant CaV1.2
a1-subunits (I1150A, I1153A, I1156A, M1160A, F1164A,
V1165A, I1460A, I1464A, Y1463F, F1117G, E1118Q, E1419Q;
Hockerman et al., 2000) with auxiliary b2a, a2d subunits (Ellis
et al., 1988). The transfection of tsA-201 cells was performed
using the FuGENE 6 transfection reagent (Roche Applied
Science, Indianapolis, IN, USA) following standard protocols.
Ionic current recordings and data acquisition
Barium currents (IBa) through voltage-gated Ca
2+ channels
were recorded at 22–25°C using the whole cell patch-clamp
conﬁgration (Hamill et al., 1981) by Axopatch 200A patch
clamp ampliﬁer (Axon Instruments, Union City, CA, USA)
36–48 h after transfection. The extracellular bath solution
contained 20 mM BaCl2, 1 mM MgCl2, 10 mM HEPES and
140 mM choline-Cl, titrated to pH 7.4 with methanesul-
phonic acid. The borosilicate glass patch pipettes (HARVARD
APPARATUS, Holliston, MA, USA) with resistances of 1–4 MW
were pulled and polished using a DMZ universal puller (Zeitz
Instruments, Martinsried, Germany), and were ﬁlled with
BJP
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10 mM HEPES and 10 mM EGTA, titrated to pH 7.25 with
CsOH.
Intracellular application was done via the patch pipettes
and IBa were recorded 5 min after the whole cell conﬁguration
was established. To ensure that the internal drug concentra-
tion reached steady state, use-dependent block was moni-
tored after different time intervals. An approximation of the
time for intracellular perfusion (Mathias et al., 1990) predicts
that under our experimental conditions, an equilibrium
between the pipette concentration of qDil and the intracel-
lular solution should be reached within about 10 s.
For extracellular application, the drug was applied to
cells under voltage clamp using a microminifold perfusion
system (ALA scientiﬁc Instruments, Westbury, NY, USA).
IBa were recorded by applying repetitive pulses after a
5 min equilibration period in drug-containing solution.
Use-dependent Ca
2+ channel block was estimated as peak
IBa inhibition during a train of short (100 ms) test pulses
from -80 mV at a frequency of 0.2 Hz. The dose–response
curves of IBa inhibition were ﬁtted using the Hill equation,
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, where IC50 is the concentra-
tion at which IBa inhibition is half-maximal, C is the applied
drug concentration, B represents a non-blocked current and
A the blocked current fraction (both in per cent). Channel
block levels observed in the presence of drug were corrected
by subtracting the mean steady-state inhibition (after 20
pulses, see Table 1) in controls. All data were digitized using a
DIGIDATA 1200 interface (Axon Instruments), smoothed by
means of a 4-pole Bessel ﬁlter, and stored on computer hard
disc. Leak currents were subtracted digitally using average
values of scaled leakage currents elicited by a 10 mV hyper-
polarizing pulse. Series resistance and offset voltage were rou-
tinely compensated. The pClamp software package (version
7.0 Axon Instruments Inc.) was used for data acquisition and
preliminary analysis.
The voltage-dependence of activation was determined
from current–voltage (I-V) curves in the absence and presence
of drug. The curves were ﬁtted according to the following
modiﬁed Boltzmann term:
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where Vrev, extrapolated reversal potential; V, membrane
potential; I, peak current; Gmax, maximum membrane con-
ductance; V0.5, act, voltage for half-maximal activation; and kact,
slope factor.
The voltage-dependence of IBa inactivation (inactivation
curve) in the presence and absence of drug was measured
using a multistep protocol (see Hohaus et al., 2005). In order
to avoid accumulation of channel block, the pulse sequence
was applied every 2 min from a holding potential of -80 mV.
Inactivation curves were drawn according to a Boltzmann
equation:
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where V, membrane potential; V0.5,inact, midpoint voltage; kinact,
slope factor and Iss, fraction of non-inactivating current.
Recovery from block was monitored by applying six short
(20 ms) test pulses after the conditioning train. Application
of the monitoring pulses in the presence of 300 mMo ft h e
used drugs did not induce measurable channel inhibition.
Analysis and curve ﬁtting was performed with Microcal
Origin 7.0. Data are given as mean  SE. Statistical signiﬁ-
cance was assessed using Student’s unpaired t-test.
Results
To clarify the interaction of diltiazem with either an extra-
or intracellular binding site on CaV1.2, the membrane-
impermeable qDil was synthesized (see Methods). CaV1.2
composed of wild-type or mutant a1 subunits and auxiliary
a2-d and b2a subunits were expressed in tsA 201 cells. qDil
was applied intracellularly via the patch pipette and extracel-
lularly in the perfusion bath.
Quaternary Dil blocks CaV1.2 when applied
to the intracellular side and had only weak
effects when applied to the extracellular side
of the membrane
As shown in Figure 1A, qDil blocked IBa in a use-dependent
manner when applied via the patch pipette. IBa inhibition was
induced by applying a train of 100 ms test pulses from
-80 mV to 20 mV at a frequency of 0.2 Hz. Figure 1C and D
illustrates the acceleration of the current decay (statistically
not signiﬁcant) during the ﬁrst pulse. Current traces from
control cells and ﬁrst pulse currents of a train with qDil in the
pipette were normalized and averaged. The direct comparison
of control IBa and IBa in the presence of drug was not possible
under these conditions.
Table 1
Peak current decay in the absence of drug after 20 pulses (100 ms)
at 0.2 Hz
Mutation Control inhibition, %
Wild-type 5.9  3.0
I1150A 3.6  1.5
I1153A 9.9  2.1
I1156A 9.3  1.8
M1160A 14.8  1.6
F1164A 10.1  3.3
V1165A 0.7  1.8
I1460A 10.6  0.9
Y1463F 0.9  1.2
M1464A 0.7  3.0
F1117G 9.5  1.2
E1118Q 9.2  1.8
E1419Q 3.6  4.8
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qDil from the intracellular side, we compared the peak
current densities in control and after a 3-min intracellular
application of qDil (300 mM). The mean peak current densi-
ties of -14.7  0.9 (control) and -13.8  0.9 pA·pF
-1 (calcu-
lated from ﬁrst pulse IBa with 300 mM qDil in the pipette)
suggest that qDil when applied from the intracellular side of
the membrane only induces non-signiﬁcant resting state
inhibition. We cannot exclude the possibility that the
reduced peak current density reﬂects open channel inhibition
developing during the rising phase of current.
The kinetics of peak current inhibition during pulse trains
and the ﬁnal steady-state values were dependent on qDil
concentration. The steady-state values plotted versus the
applied drug concentrations are shown in Figure 1B. The IC50
values for IBa inhibition of wild-type CaV1.2 by qDil and Dil
were 95  5 mM and 85  9 mM respectively (Figure 1B).
Extracellular application of 300 mM qDil induced 10  4%
use-dependent IBa inhibition of wild-type CaV1.2 (Figure 2A
and B), which was not signiﬁcantly different from the current
decay during a pulse train in the absence of drug (6  3%).
The same drug concentration induced 59  4% inhibition of
IBa when applied via the pipette, indicating that qDil accesses
its binding site on CaV1.2 from the intracellular side of the
membrane (Figure 1B).
The tonic block of IBa (current inhibition after 3 min in
drug at rest) induced by 100 and 300 mM Dil and qDil is shown
inFigure 2D.Neither100nor300 mMofqDilinducedsubstan-
tial IBa inhibition (12  2% and 16  2% respectively). This
block was not enhanced by repetitive pulsing. Extracellularly
applied Dil induced larger tonic current inhibition than qDil,
which can be prescribed to channel inhibition by the neutral
form of the drug (see Smirnov and Aaronson, 1998).
Intracellularly applied 300 mM SQ32,428 (a quaternary
benzothiazepine, see also Hering et al., 1993) induced
minimal channel inhibition (Figure 2C). The structures of
qDil and SQ32,428 are compared in Figure 2B. Externally
applied SQ32,428 (100 and 300 mM) inhibited IBa by 23  2%
(n = 5) and 43  3% (n = 5), respectively, in a non-use-
dependent manner (Figure 2D, see Hering et al., 1993 for
similar experiments on BC3H1 cells).
qDil interaction with the diltiazem
binding site
SixaminoacidresiduesonsegmentIIIS6andthreeresidueson
segment IVS6 (Figure 3A) of the CaV1.2 a1 subunit have been
shown to affect channel inhibition by Dil (Hering et al., 1996;
Hockerman et al., 2000; Dilmac et al., 2003). To elucidate
whether its quaternary derivative interacts with the same
binding pocket, we ﬁrst studied IBa inhibition in IIIS6 mutants
Figure 1
Use-dependent block of CaV1.2 by intracellularly applied quaternary diltiazem. (A) Use-dependent inhibition of wild-type channels measured in
the absence or presence of 50, 100, 300 or 500 mM quaternary diltiazem in the intracellular (pipette) solution. Data points are the mean from 4–6
experiments. (B) The IC50 values [d-cis-diltiazem: 95  5 mM (Hill slope nH = 1.6  0.4) and quaternary derivative of d-cis-diltiazem (qDil): 85 
9 mM( nH = 1.3  0.2) ] were obtained by ﬁtting the data points to the Hill equation (as described in Methods). Channel block was estimated as
peak IBa inhibition during trains of 20 pulses (0.2 Hz, 100 ms) applied from a holding potential of -80 mV to +20 mV in control (Table 1) and in
the presence of quaternary diltiazem. (C) Superimposed IBa during a train of 20 pulses with 300 mM quaternary diltiazem in pipette. (D)
Acceleration of current decay during the ﬁrst pulse in train. Current traces were normalized and averaged. The mean peak current densities were
-14.7  0.9 (control) and -13.8  0.9 pA·pF
-1 (ﬁrst pulse current after 3 min of 300 mM qDil in the pipette). Histograms indicate remaining
current at the end of the ﬁrst pulse.
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intracellularly applied qDil. Three mutants (I1150A, F1164A,
V1165A) signiﬁcantly reduced sensitivity for qDil (Figure 3B
and C), which is in line with their strong effects on Dil
sensitivity (Hockerman et al., 2000). The other mutations
induced moderate (not statistically signiﬁcant) effects, which
might reﬂect the different experimental conditions. Rare
pulsing every 20 s (0.05 Hz) from -60 mV induces predomi-
nantly tonic block (Hockerman et al., 2000), while frequent
pulsing every 5 s (0.2 Hz) induces predominantly use-
dependent block (present study). Mutations of the key deter-
minants of Dil sensitivity in segment IVS6 (I1460A, Y1463F
andM1464A,Hockermanet al.,2000)allsigniﬁcantlyreduced
qDil sensitivity (Figure 3D and E). To determine a possible
interaction of qDil with potential binding sites in the selectiv-
ity ﬁlter, we analysed IBa inhibition of mutants F1117G,
E1118Q and E1419Q. A moderate reduction in block com-
pared with wild-type was observed (Figure 3F and G), which is
in line with the results from a study by Dilmac et al. (2003).
Modulation of channel gating by quaternary
and tertiary diltiazem
To obtain insights into the link between state-dependent
inhibition and channel gating, we measured the standard
characteristics of channel gating in control conditions and in
the presence of a drug. The activation and inactivation curves
are shown in Figure 4. Neither Dil (extracellular application)
nor qDil (intracellular application) affected the activation
curve of CaV1.2 (Figure 4A, Table 2) and neither of them
affected the kinetics of current activation and deactivation
(data not shown). In line with previous studies, we observed
a leftward shift of the inactivation curve by 300 mM Dil (5.0 
1.5 mV). Quaternary diltiazem applied at the same concen-
tration from the intracellular side induced a very similar shift
(7.1  1.3 mV) suggesting similar state-dependency of both
compounds (Figure 4B).
Recovery from block by qDil and Dil was compared at a
holding potential of -80 mV. Figure 5 illustrates the very simi-
lar recovery from block by intracellular qDil and extracellu-
larlyappliedDil[t(qDil)=37.14.9 svs.t(Dil)=32.35.2 s].
Discussion
CaV1.2 displays a high sensitivity to calcium antagonists such
as DHPs, PAAs and diltiazem (Striessnig et al., 1991; Hocker-
man et al., 1997; Catterall et al., 2005). Calcium antagonists
are used clinically to treat hypertension and angina pectoris
(Fleckenstein and Fleckenstein-Grun, 1980, Triggle, 2007)
PAAs and diltiazem are also used as anti-arrhythmics and
block L-type (CaV1.2) channels more efﬁciently at higher
frequencies (Lee and Tsien, 1983).
Putative diltiazem binding determinants were identiﬁed
on pore forming segments IIIS6 and IVS6 and the selectivity
ﬁlter region (Hering et al., 1996; Kraus et al., 1998; Berjukow
et al., 1999; Hockerman et al., 2000; Dilmac et al., 2003). A
Figure 2
Extracellular quaternary diltiazem and intracellular [quaternary benzothiazepine [(cis)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-3-methyl-6-
(triﬂuoromethyl)-1-[2-trimethylammonio)ethyl]-2H-1-benzazepin-2-o ne] (SQ32,428) ] do not inhibit CaV1.2. (A) Superimposed IBa during a train
of 20 pulses (same protocol as in Figure 1) in the absence of drug, with 300 mM quaternary diltiazem in the bath solution and with 300 mM
SQ32,428 in pipette. (B) Structures of quaternary diltiazem and benzothiazepinone SQ32,428. (C) Lack of signiﬁcant IBa inhibition by extracel-
lularly applied quaternary derivative of d-cis-diltiazem (qDil) (300 mM) and intracellularly applied SQ32,428 (300 mM). Peak current decay with
300 mM qDil in the pipette is shown for comparison as a broken line (data from Figure 1A). Data points are the mean from 4–6 experiments. (D)
Illustrates tonic IBa inhibition (block after 3 min in drug at rest at -80 mV) induced by 100 and 300 mM Dil, d-cis-diltiazem (Dil) and SQ32,428
applied extracellularly.
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Mutations of the putative d-cis-diltiazem binding site affect IBa inhibition by intracellularly applied quaternary derivative of d-cis-diltiazem (qDil).
(A) Amino acid sequence of the transmembrane segments IIIS6 and IVS6 of the CaV1.2 a1 subunit. Putative diltiazem binding determinants are
highlighted. (B) Peak current decay in mutants I1150A, I1153A and V1165A channels induced by 300 mM quaternary diltiazem in the pipette
solution (protocol as in Figure 1). (C) Remaining currents after 20 pulses in wild-type (WT) and the indicated IIIS6 mutants. Asterisks denote that
the steady-state block value for quaternary diltiazem of the indicated mutant channel is signiﬁcantly different from that of WT (Student’s t-test:
*P < 0.05, **P < 0.01, #P = 0.057). (D) Use-dependent inhibition of I460A and M1464A channels by 300 mM of qDil in the pipette solution. (E)
Remaining currents of WT CaV1.2 and the indicated IVS6 mutants. Asterisks indicate that the steady-state block value for quaternary diltiazem of
the indicated mutant channel is signiﬁcantly different from that of WT (Student’s t-test: *P < 0.05, **P < 0.01). (F) Use-dependent inhibition of
selectivity ﬁlters mutants F1117G, E1118Q and E1419Q by 300 mM qDil in the pipette solution. (G) Remaining currents after 20 pulses in WT and
the indicated CaV1.2 mutants in 100 and 300 mM qDil in the pipette. Asterisks indicate where there is a signiﬁcant difference between the
steady-state block of the indicated mutant channel and the WT (Student’s t-test: *P < 0.05, #P = 0.057). The broken lines in (B, D and F) represent
peak current inhibition in wild-type (taken from Figure 1A). Channel block in (C, E and G) was estimated by subtracting ‘steady state’ inhibition
after 20 pulses in drug-free solution (Table 1) from channel block induced by 100 mM or 300 mM of qDil.
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was revealed in studies with mutant and chimerical CaV1.2
constructs (Berjukow et al., 1999; Motoike et al., 1999; Dilmac
et al., 2003). Like PAAs, diltiazem blocks CaV1.2 channels in a
use-dependent manner (Lee and Tsien, 1983; Hockerman
et al., 2000). The molecular mechanism of channel inhibition
and the access path of diltiazem to its receptor site are,
however, less well understood. A quaternary BTZ (SQ32,428,
Figure 1D) was shown to block L-type channels in BC3H1
cells when applied from the extracellular side of the mem-
brane in a non-use-dependent manner (Hering et al., 1993).
Extracellular application of 100 and 300 mM of SQ32,428 on
Figure 4
Changes in channel gating induced by d-cis-diltiazem (Dil) and quaternary derivative of d-cis-diltiazem (qDil). Steady-state activation (A) and
inactivation (B) of wild-type (WT) in the absence (control) or presence of 300 mM qDil applied from intracellular side or 300 mM of Dil applied by
bath perfusion (see Table 2 for parameters of the Bolzmann distributions).
Table 2
Effects of quaternary derivative of d-cis-diltiazem (qDil) and d-cis-diltiazem (Dil) on voltage-dependent gating of CaV1.2
Wild-type V0.5,act,m V k act,m V V 0.5,inact,m V k inact,m V r 1000,%
Control -6.4  0.7 5.6  0.6 -41.4  1.0 7.4  0.9 69  6
300 mM qDil (intracellular) -6.3  0.7 5.3  0.7 -48.5  0.9 7.7  0.8 44  11
300 mM Dil (extracellular) -8.2  0.8 6.2  0.7 -46.4  1.2 7.2  1.1 38  10
Midpoints and slope factors of the activation and inactivation curves and remaining current after 1000 ms pulse (r1000)a t0m Vp u l s e( n = 3–6).
Figure 5
Recovery of wild-type CaV1.2 from block by intracellularly applied quaternary derivative of d-cis-diltiazem (qDil) and extracellularly applied
d-cis-diltiazem (Dil). (A–B) Recovery from block by 300 mM intracellular quaternary or 300 mM extracellular tertiary diltiazem at -80 mV holding
potentials. Block was elicited by a standard conditioning train of 20 pulses in the presence of qDil and recovery monitored by applying short
(20 ms) test pulses at different times after the train. The mean time constants of recovery from block by Dil and qDil were 32.3  5.2 (n = 7) and
37.1  4.9 (n = 9) respectively.
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ﬁrmed this observation. Tikhonov and Zhorov (2008)
hypothesized that access of the ‘bulky BTZs’ is unlikely to
occur through the open activation gate from the intracellular
side and proposed a ‘side walk’ access of BTZ molecules from
the extracellular side via the III/IV domain interface to their
binding site in the pore. As shown in Figure 1, qDil inhibited
IBa predominantly when applied to the intracellular side of
the membrane. The estimated tonic inhibition by intracellu-
larly applied qDil was small (current density of -14.7 
0.9 pA·pF
-1 in control vs. -13.9  1.1 pA·pF
-1 after ﬁrst pulse
in the presence of 300 mM qDil). Extracellular application (up
to 300 mM) did not induce a use-dependent effect (Figure 2C)
and produced only a low level of tonic current inhibition
(Figure 2D). The more pronounced tonic IBa inhibition
induced by Dil (Figure 2D) contributes to its concentration–
inhibition relationship. This is evident from Figure 1B, where
stronger IBa inhibition by Dil was particularly evident at high
drug concentrations (See Figure 2D).
Our principle ﬁnding that intracellularly applied qDil
accesses its binding site through the open activation gate is in
line with the data of Smirnov and Aaronson (1998); they
suggested that use-dependent current inhibition is induced
by the charged form of diltiazem from inside. Furthermore,
intracellular channel inhibition by qDil was modulated by
four IIIS6 and three IVS6 mutations that have previously been
identiﬁed as putative diltiazem binding determinants. Selec-
tivity ﬁlter mutations less efﬁciently prevented channel
block, which is in line with Dilmac et al. 2003.
Taken together, these data support a scenario where intra-
cellularly applied qDil and extracellularly applied Dil interact
with the same or largely overlapping binding pockets in the
channel pore (Figure 3).
Intracellular access of the permanently charged qDil to its
binding site seems to occur in a very similar way to that
previously shown for quaternary PAAs. Quaternary PAAs
approach their binding site on CaV1.2 from the intracellular
face of the plasma membrane and repeated channel opening
facilitates access of PAAs to the pore region, which explains
use-dependent block (Hescheler et al., 1982; Berjukov et al.,
1996; Beyl et al., 2007). The access path of charged 1,4 DHPs
occurs, however, via a pathway from the extracellular site of
the membrane. Amlodipine in its ionized form and the per-
manently charged quaternary DHP derivative SDZ 207–180
were found to be ineffective when applied intracellularly,
suggesting that the DHP receptor site is inaccessible from the
intracellular surface, while extracellular application of these
compounds resulted in channel block indicating that these
antagonists gain access to the receptor site via an extracellular
pathway (Kass et al., 1991, see Hockerman et al. 1997 for
review). It is tempting to speculate that DHPs reach their
receptor determinants in the pore via the ‘side walk’ access
proposed by Tikhonov and Zhorov (2008).
Similar state-dependency of Cav1.2 inhibition
by qDil and Dil
High-afﬁnity binding to open and inactivated channel states
are important characteristics of use-dependent channel
blockers. In order to analyse drug access via the intracellular
channel mouth, we have co-expressed the a1 subunit of
Cav1.2 with the b2a subunit, which is known to prolong the
open state by minimizing channel inactivation. As shown in
Figure 1C and D, the absence of inactivation during short
pulses did not prevent use-dependent channel block suggest-
ing access of qDil to its binding site via the open gate. Block
development was slow and equilibrated at 300 mM during 15
pulses (Figure 1A). Slow block development is also evident
from the acceleration of the current decay with 300 mM qDil
in the pipette (Figure 1D) and the non-signiﬁcant changes in
the steady-state activation curve (Figure 4A) (see also Lee and
Tsien, 1983). However, channel inhibition is modulated by
inactivation, as evident from the shifts of the availability
curves in Figure 4B (see also Zhang et al., 2010).
Accumulation of channel inhibition during a pulse train,
as illustrated in Figure 1A, depends on channel recovery
between pulses. Recovery from use-dependent block by qDil
and Dil was found to be very similar [Figure 5, t(qDil) = 37.1
 4.9 s vs. t(Dil) = 32.3  5.2 s]. Similar recovery from block
and similar apparent afﬁnities [IC50(Dil) = 95  5 mM and
IC50(qDil) = 85  9 mM] support the hypothesis that both
compounds interact with identical or largely overlapping
binding determinants in the channel pore.
The differences in tonic block observed for Dil and qDil
warrants further research. The negligible ‘intracellular tonic IBa
inhibition’ induced by intracellular qDil (current density of
-14.70.9 pA·pF
-1incontrolvs.-13.91.1 pA·pF
-1afterﬁrst
pulseinthepresenceof300 mMqDil)suggeststhatthecharged
form induces predominantly use-dependent block, while the
neutral form may be responsible for tonic inhibition (see also
Smirnov and Aaronson, 1998). Access of the neutral form of
Dil to its binding determinants in the pore via the ‘side walk’
access (Tikhonov and Zhorov, 2008) cannot be excluded.
Conclusions and outlook
Data from the present study demonstrate intracellular access
of quaternary (membrane-impermeable) diltiazem and the
interaction of qDil with determinants of the binding pocket
previously identiﬁed for tertiary diltiazem (Hering et al.,
1996; Hockerman et al., 2000; Dilmac et al., 2003). Quater-
nary diltiazem accesses its binding determinants via the inner
channel mouth in a similar manner as was previously found
with quaternary PAAs. Our data suggest that use-dependent
block of CaV1.2 by diltiazem occurs predominantly via the
open channel conformation.
Our study also permits new insights into the structure–
activity relationship of this therapeutically important drug. A
structurally related BTZ (SQ32,428) had no effect when
applied from the cytosolic side (Figure 2A and C, see also
Hering et al., 1993). Compared with SQ32,428, the C5 of qDil
is replaced by a sulphur atom and the triﬂuoromethyl group
in position C6 is substituted by a hydrogen atom. Addition-
ally, the methyl group of SQ32,428 in position C3 is replaced
by an acetoxy group (Figure 2B). Any of these apparently
small structural differences may be essential for interaction
of Dil with its intracellularly or extracellularly accessible
binding sites. Tikhonov and Zhorov (2008) proposed an inter-
esting concept as to how the functional groups of BTZ may
interact with individual amino acid residues in the pore.
Derivatives of quaternary diltiazem (with individually
replaced moieties) may thus represent interesting tools for
investigating the molecular basis of use-dependent drug inter-
actions with intracellular accessible binding determinants.
BJP
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